ES2584858T3 - Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol - Google Patents
Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol Download PDFInfo
- Publication number
- ES2584858T3 ES2584858T3 ES14150805.1T ES14150805T ES2584858T3 ES 2584858 T3 ES2584858 T3 ES 2584858T3 ES 14150805 T ES14150805 T ES 14150805T ES 2584858 T3 ES2584858 T3 ES 2584858T3
- Authority
- ES
- Spain
- Prior art keywords
- days
- hours
- polyol
- composition
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición oftálmica de múltiples dosis que comprende: brinzolamida, brimonidina o una combinación de las mismas como agente terapéutico; un primer poliol, seleccionándose el primer poliol de manitol, sorbitol o una combinación de los mismos, siendo la concentración del primer poliol de al menos el 0,01% en p/v pero no mayor del 0,5% en p/v; un segundo poliol, seleccionándose el segundo poliol de propilenglicol, glicerina o una combinación de los mismos, siendo la concentración del segundo poliol de al menos el 0,1% en p/v pero menor del 5% en p/v de la composición; una cantidad eficaz de borato, siendo la cantidad eficaz de al menos el 0,05% en p/v y menor del 0,5% en p/v de la composición global; BAC como conservante antimicrobiano, siendo la concentración de BAC en la composición mayor del 0,00001% en p/v pero menor del 0,0035% en p/v; y agua.
Description
pueden usarse para suspensiones oftálmicas de fármacos tales como brinzolamida, roscovitina, amfenac amida, dexametasona, inhibidor de bradicinina, acetato de anecortavo, tandospirona, combinaciones de los mismos y sus combinaciones con otros fármacos.
Tabla C: ejemplos A a C con el 0,002% de BAC
- Composición
- A COMPARATIVO B COMPARATIVO C
- Carbómero 974 P
- 0,45 0,45 0,45
- Tiloxapol
- 0,025 0,025 0,025
- Ácido bórico
- 0,3 0,6 0,3
- Manitol
- 0,3 2,0 2
- Propilenglicol
- 0,75 1 0,75
- Cloruro de sodio
- 0,3 Ninguno Ninguno
- Cloruro de benzalconio
- 0,002 0,002 0,002
- Edetato de disodio
- Ninguno Ninguno Ninguno
- Hidróxido de sodio/HCl
- pH 7,0 pH 7,0 pH 7,0
- Agua purificada
- CS CS CS
- Osmolalidad
- 279 324 259
- Viscosidad (cps) a 120 s-1
- 49,6 68,2 127,9
- Viscosidad (cps) a 12 s-1
- 144,4 210,4 480,7
- Microorganismos, tiempo
- Criterios de la Ph. Eur. A Criterios de la Ph. Eur. B Reducciones log
- S. aureus 6 horas 24 horas 7 días 14 días 28 días
- 2,0 3,0 NRa -1,0 3,0 NIb 4,6 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 2,5 4,9 4,9 4,9 4,9
- P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
- 2,0 3,0 NR -1,0 3,0 NI 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 4,8 4,8 4,8 4,8 4,8
- E. colic 6 horas 24 horas 7 días 14 días 28 días
- NAd NA 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 3,0 5,0 5,0 5,0 5,0
- C. albicans 7 días 14 días 28 días
- 2,0 NI NI -1,0 NI 4,7 4,7 4,7 4,7 4,7 4,7 4,8 4,8 4,8
- A. niger 7 días 14 días 28 días
- 2,0 NI NI -1,0 NI 3,1 3,6 5,2 3,1 4,2 5,2 3,7 4,3 5,1
- aNR = Sin recuperación bNI = Sin aumento cLa Ph. Eur. No tiene requisito para E. Coli dNA = No aplicable
Ejemplo D
El ejemplo D presentado en la tabla 3 es una composición con el 0,002% de BAC, ácido bórico y dos polioles diferentes y se proyecta para cumplir con los criterios de PET de la Ph. Eur B y A.
Tabla D: Ejemplo D con el 0,002% de BAC
- Composición
- D
- Ácido bórico
- 0,3
- Sorbitol
- 0,25
- Propilenglicol
- 1,6
10
- Cada una de las composiciones H-J, entre otros usos, puede usarse como vehículos de suspensión para suspender agentes terapéuticos.
- Composición
- H I J
- Cloruro de sodio
- 0,15 0,3 Ninguno
- Cloruro de benzalconio
- 0,001 0,001 0,001
- Hidróxido de sodio/HCl
- pH 7,0 pH 7,0 pH 7,0
- Agua purificada
- CS CS CS
- Osmolalidad
- 278 274 278
- Viscosidad (cps) a 120 s-1
- 63,1 53,8 59,1
- Viscosidad (cps) a 12 s-1
- 169 149 172
- S. aureus 6 horas 24 horas 7 días 14 días 28 días
- 0,2 2,6 5,0 5,0 5,0 0,0 1,4 5,0 5,0 5,0 0,2 3,0 5,0 5,0 5,0
- P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
- 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9 4,9
- E. coli 6 horas 24 horas 7 días 14 días 28 días
- 1,4 3,1 5,0 5,0 5,0 1,4 3,4 5,0 5,0 5,0 3,1 5,0 5,0 5,0 5,0
- C. albicans 7 días 14 días 28 días
- 3,0 4,3 4,8 3,5 4,8 4,8 4,8 4,8 4,8
- A. niger 7 días 14 días 28 días
- 3,2 3,7 3,6 3,5 3,4 3,0 3,6 3,5 3,4
Tabla G: Formulaciones de roscovitina con baja cantidad de BAC, ácido bórico y dos polioles
- Composición
- K
- Roscovitina (AL-39256)
- 1
- Carbómero 974P
- 0,45
- Tiloxapol
- 0,025
- Ácido bórico
- 0,3
- Manitol
- 0,3
- Propilenglicol
- 0,75
- Cloruro de sodio
- 0,28
- Cloruro de benzalconio
- 0,003
- Hidróxido de sodio/HCl
- pH 7,2
- Agua purificada
- CS
- Osmolalidad (mOsm/kg)
- 271
- Viscosidad (cps) a 12 s-1
- 198,1
- Viscosidad (cps) a 120 s-1
- 66,5
- S. aureus
- 6 horas 24 horas 7 días 14 días 28 días 5,1 5,1 5,1 5,1 5,1
- P. aeruginosa
- 6 horas 24 horas 7 días 14 días 28 días 4,9 4,9 4,9 4,9 4,9
- E. colic
- 6 horas 4,9
12
- Composición
- K
- 24 horas
- 4,9
- 7 días
- 4,9
- 14 días
- 4,9
- 28 días
- 4,9
- C. albicans
- 7 días 4,8
- 14 días
- 4,8
- 28 días
- 4,8
- A. niger
- 7 días 5,1
- 14 días
- 5,1
- 28 días
- 5,1
La composición K presenta una resistencia a la normalización de lágrimas de aproximadamente 4,4.
Tabla H: Formulaciones de brinzolamida y brinzolamida/brimonidina con baja cantidad de BAC, ácido bórico y dos polioles
- Composición
- M N
- Brinzolamida
- 1,0 1,0
- Brimonidina
- 0,15 0,15
- Carbopol 974P
- 0,4 0,4
- Tiloxapol
- 0,025 0,025
- Ácido bórico
- 0,3 0,3
- Manitol
- 0,3 0,3
- Propilenglicol
- 0,75 0,75
- Cloruro de sodio
- 0,23 0,23
- Cloruro de benzalconio
- 0,003 0,003
- Hidróxido de sodio y/o ácido clorhídrico
- CS para pH 6,5 ± 0,2 CS para pH 6,5 ± 0,2
- Agua purificada
- CS hasta el 100% CS hasta el 100%
- S. aureus 6 horas 24 horas 7 días 14 días 28 días
- 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
- P. aeruginosa 6 horas 24 horas 7 días 14 días 28 días
- 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
- E. colic 6 horas 24 horas 7 días 14 días 28 días
- 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0
- C. albicans 7 días 14 días 28 días
- 4,8 4,8 4,8 4,8 4,8 4,8
- A. niger 7 días 14 días 28 días
- 4,3 4,1 4,2 4,4 4,3 4,1
Tabla I: Ejemplo O a V
Las composiciones M y N presentan una resistencia a la normalización de lágrimas de aproximadamente 18.
Los ejemplos O a V muestran que tanto la osmolalidad como la viscosidad de formulaciones que contienen carbómero pueden obtenerse en el intervalo deseado usando cloruro de sodio al tiempo que se mantiene la concentración de sodio inferior al 0,4%.
13
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US218472P | 2000-07-14 | ||
US21847209P | 2009-06-19 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2584858T3 true ES2584858T3 (es) | 2016-09-29 |
Family
ID=42364357
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14150805.1T Active ES2584858T3 (es) | 2009-06-19 | 2010-06-17 | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol |
ES16159225T Active ES2803648T3 (es) | 2009-06-19 | 2010-06-17 | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol |
ES10727317.9T Active ES2461617T3 (es) | 2009-06-19 | 2010-06-17 | Composiciones farmacéuticas acuosas que contienen complejos borato-polioles |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16159225T Active ES2803648T3 (es) | 2009-06-19 | 2010-06-17 | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol |
ES10727317.9T Active ES2461617T3 (es) | 2009-06-19 | 2010-06-17 | Composiciones farmacéuticas acuosas que contienen complejos borato-polioles |
Country Status (27)
Country | Link |
---|---|
US (3) | US9044484B2 (es) |
EP (4) | EP3437634A1 (es) |
JP (3) | JP6017956B2 (es) |
KR (1) | KR101738502B1 (es) |
CN (2) | CN104707145A (es) |
AR (2) | AR077126A1 (es) |
AU (1) | AU2010262898B2 (es) |
BR (1) | BRPI1015996B8 (es) |
CA (1) | CA2763778C (es) |
CL (1) | CL2010000634A1 (es) |
CY (2) | CY1117835T1 (es) |
DK (3) | DK2722035T3 (es) |
ES (3) | ES2584858T3 (es) |
HK (2) | HK1163521A1 (es) |
HR (2) | HRP20160953T1 (es) |
HU (2) | HUE030435T2 (es) |
LT (1) | LT3045164T (es) |
MX (1) | MX2011013107A (es) |
PL (3) | PL2442790T3 (es) |
PT (3) | PT2722035T (es) |
RU (1) | RU2563125C2 (es) |
SI (3) | SI3045164T1 (es) |
SM (1) | SMT201600249B (es) |
TW (1) | TWI489997B (es) |
UY (1) | UY32709A (es) |
WO (1) | WO2010148190A1 (es) |
ZA (1) | ZA201108384B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2254549T4 (da) * | 2008-03-17 | 2019-07-22 | Alcon Res Ltd | Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser |
TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
CN103379904A (zh) * | 2011-01-18 | 2013-10-30 | 千寿制药株式会社 | 具有保存效能的溴芬酸水性液剂组合物 |
WO2012145470A2 (en) | 2011-04-22 | 2012-10-26 | Alcon Research, Ltd. | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
EP2699228A2 (en) | 2011-04-22 | 2014-02-26 | Alcon Research, Ltd. | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
US20120312840A1 (en) * | 2011-05-13 | 2012-12-13 | Ayako Hasegawa | Container closure system with integral antimicrobial additives |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
WO2014121028A1 (en) | 2013-02-01 | 2014-08-07 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
US9795560B2 (en) | 2013-02-01 | 2017-10-24 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
US9693563B2 (en) | 2013-08-20 | 2017-07-04 | 3M Innovative Properties Company | Boron-silane polyether complex |
WO2017217450A1 (ja) * | 2016-06-15 | 2017-12-21 | 千寿製薬株式会社 | 眼科用医薬製品 |
JP6247430B1 (ja) * | 2016-06-15 | 2017-12-13 | 千寿製薬株式会社 | 眼科用医薬製品 |
CN106237337B (zh) * | 2016-08-05 | 2019-11-08 | 河南中帅医药科技股份有限公司 | 一种液体药物制剂用防腐组合物 |
GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
JP7413040B2 (ja) | 2018-02-21 | 2024-01-15 | 三菱重工サーマルシステムズ株式会社 | スクロール流体機械及びその設計方法 |
KR20210096096A (ko) | 2018-10-26 | 2021-08-04 | 오큐파이어 파마, 인크. | 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물 |
EP3769753B1 (en) | 2019-07-23 | 2021-11-17 | Nicox Ophthalmics, Inc. | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions |
US20230218611A1 (en) | 2020-04-29 | 2023-07-13 | Sentiss Pharma Private Limited | Ophthalmic compositions comprising a combination of brinzolamide and brimonidine |
US20220105101A1 (en) | 2020-10-05 | 2022-04-07 | Somerset Therapeutics, Llc | Efficient brinzolamide and brimonidine compositions |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931319A (en) * | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
US4027020A (en) * | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
GB2084870B (en) * | 1980-10-10 | 1985-05-09 | Muhlemann R Hans | Oral compositions containing pyrimidine amine compounds and zinc salts |
US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
US4407791A (en) * | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US5607698A (en) * | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
US5037647A (en) * | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
IL92351A (en) * | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
JP3058656B2 (ja) | 1990-06-18 | 2000-07-04 | トーメー産業株式会社 | コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法 |
UA26334A (uk) * | 1990-12-27 | 1999-08-30 | Еллергаh Іhк. | Спосіб дезиhфекції коhтактhих ліhз та композиція для дезиhфекції коhтактhих ліhз |
US5460834A (en) * | 1991-12-13 | 1995-10-24 | Alcon Laboratories, Inc. | Combinations of polymers for use in physiological tear compositions |
JP2873530B2 (ja) * | 1991-12-13 | 1999-03-24 | 参天製薬株式会社 | ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤 |
DK0639070T4 (da) | 1992-05-06 | 2010-12-13 | Alcon Lab Inc | Anvendelse af borat-polyolkomplekser til ophtalmiske præparater |
US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5300287A (en) * | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
US5320843A (en) * | 1992-12-10 | 1994-06-14 | Polymer Technology Corporation | Method for improving antibacterial properties of ophthalmic solutions |
CA2088927A1 (en) | 1993-02-11 | 1994-08-12 | Donald Skeffington | Preservative system for vitamin e aqueous solution |
US5736165A (en) * | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
TW274516B (es) * | 1993-11-12 | 1996-04-21 | Ciba Geigy Ag | |
WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US5603929A (en) * | 1994-11-16 | 1997-02-18 | Alcon Laboratories, Inc. | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
US6024954A (en) * | 1994-12-12 | 2000-02-15 | Allergan | Compositions and methods for disinfecting contact lenses and preserving contact lens care products |
US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
CN1074277C (zh) * | 1995-03-20 | 2001-11-07 | 尤尼利弗公司 | 液体洁肤制剂 |
US5683993A (en) * | 1995-06-22 | 1997-11-04 | Ciba Vision Corporation | Compositions and methods for stabilizing polymers |
HU225329B1 (en) * | 1996-09-12 | 2006-09-28 | Richter Gedeon Vegyeszet | Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity |
US6121315A (en) * | 1996-09-20 | 2000-09-19 | Warner-Lambert Company | Oral compositions containing a zinc compound |
US5820822A (en) * | 1996-10-25 | 1998-10-13 | Kross; Robert D. | Antimicrobial composition and method of use |
JPH10130156A (ja) | 1996-10-30 | 1998-05-19 | Teika Seiyaku Kk | 点眼剤組成物 |
US6071904A (en) * | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
DE69713388T2 (de) * | 1996-12-13 | 2002-10-31 | Alcon Lab Inc | Verwendung von niedermolekularen aminoalkoholen in ophthalmologischen präparaten |
US5858346A (en) * | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
US6265444B1 (en) * | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
CA2296080C (en) * | 1997-07-29 | 2005-02-01 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
WO2004073708A1 (en) | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
US6034043A (en) * | 1999-04-20 | 2000-03-07 | Lever Brothers Company, Division Of Conopco, Inc. | Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness |
US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US6166012A (en) * | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
TW496745B (en) * | 2000-11-29 | 2002-08-01 | Novartis Ag | Aqueous disinfecting systems |
AR035509A1 (es) | 2000-12-21 | 2004-06-02 | Alcon Inc | Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento |
JP4844706B2 (ja) | 2001-03-12 | 2011-12-28 | ライオン株式会社 | 眼科用組成物 |
US6743439B1 (en) * | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
JP4863589B2 (ja) | 2001-09-28 | 2012-01-25 | ロート製薬株式会社 | 水性組成物 |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
TWI322828B (en) * | 2002-12-23 | 2010-04-01 | Alcon Inc | Use of multifunctional surface active agents to clean contact lenses |
ES2301964T3 (es) * | 2003-01-21 | 2008-07-01 | Senju Pharmaceutical Co., Ltd. | Preparado liquido acuoso que contiene acido 2-amino-3-(4-bromobenzoil)fenilacetico. |
JP4644682B2 (ja) * | 2003-12-09 | 2011-03-02 | アルコン、インコーポレイテッド | 水性組成物の抗微生物活性を強化するためのビスアミンの使用 |
AU2004305535A1 (en) | 2003-12-09 | 2005-07-07 | Alcon, Inc. | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
WO2005060933A1 (en) * | 2003-12-11 | 2005-07-07 | Alcon, Inc. | Ophthalmic compositions containing a polysaccharide/borate gelling system |
US20050214382A1 (en) | 2004-03-29 | 2005-09-29 | Erning Xia | Zinc preservative composition and method of use |
CA2583622A1 (en) * | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US20060229219A1 (en) * | 2005-04-11 | 2006-10-12 | Advanced Medical Optics, Inc. | Borate-polyol mixtures as a buffering system |
US20070212420A1 (en) | 2006-03-10 | 2007-09-13 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
WO2008002118A1 (es) * | 2006-06-27 | 2008-01-03 | Arturo Jimenez Bayardo | Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina |
US20070297990A1 (en) * | 2006-06-27 | 2007-12-27 | Shah Mandar V | Self-preserving composition |
ZA200901164B (en) * | 2006-09-21 | 2010-06-30 | Alcon Res Ltd | Self preserved aqueous pharmaceutical compositions |
TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
CN101522171A (zh) | 2006-09-28 | 2009-09-02 | 爱尔康研究有限公司 | 自身防腐的水性药物组合物 |
US20080095863A1 (en) * | 2006-10-24 | 2008-04-24 | Alcon Manufacturing Ltd. | 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions |
WO2008052037A2 (en) * | 2006-10-24 | 2008-05-02 | Alcon Research, Ltd. | Packaging materials for formulations containing 2-pyrrolidone derivatives |
US7705112B2 (en) | 2007-04-17 | 2010-04-27 | Abbott Medical Optics Inc. | Polyquaternium-1 synthesis methods |
DK2254549T4 (da) * | 2008-03-17 | 2019-07-22 | Alcon Res Ltd | Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser |
TWI544927B (zh) * | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
US7999064B2 (en) | 2009-04-23 | 2011-08-16 | Abbott Medical Optics Inc. | Polyquaternium-1 synthesis methods and associated formulations |
TWI489997B (zh) * | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
-
2010
- 2010-05-27 TW TW099116993A patent/TWI489997B/zh active
- 2010-06-14 UY UY0001032709A patent/UY32709A/es not_active Application Discontinuation
- 2010-06-16 CL CL2010000634A patent/CL2010000634A1/es unknown
- 2010-06-17 HU HUE14150805A patent/HUE030435T2/en unknown
- 2010-06-17 PL PL10727317T patent/PL2442790T3/pl unknown
- 2010-06-17 BR BRPI1015996A patent/BRPI1015996B8/pt active IP Right Grant
- 2010-06-17 EP EP18195971.9A patent/EP3437634A1/en active Pending
- 2010-06-17 EP EP14150805.1A patent/EP2722035B1/en not_active Revoked
- 2010-06-17 PL PL16159225T patent/PL3045164T3/pl unknown
- 2010-06-17 SI SI201032021T patent/SI3045164T1/sl unknown
- 2010-06-17 RU RU2012101782/15A patent/RU2563125C2/ru active
- 2010-06-17 AR ARP100102145A patent/AR077126A1/es not_active Application Discontinuation
- 2010-06-17 SI SI201031243A patent/SI2722035T1/sl unknown
- 2010-06-17 CN CN201510079734.8A patent/CN104707145A/zh active Pending
- 2010-06-17 EP EP10727317.9A patent/EP2442790B1/en not_active Revoked
- 2010-06-17 ES ES14150805.1T patent/ES2584858T3/es active Active
- 2010-06-17 US US12/817,561 patent/US9044484B2/en active Active
- 2010-06-17 AU AU2010262898A patent/AU2010262898B2/en active Active
- 2010-06-17 MX MX2011013107A patent/MX2011013107A/es active IP Right Grant
- 2010-06-17 PL PL14150805.1T patent/PL2722035T3/pl unknown
- 2010-06-17 CA CA2763778A patent/CA2763778C/en active Active
- 2010-06-17 PT PT141508051T patent/PT2722035T/pt unknown
- 2010-06-17 CN CN201080024946.1A patent/CN102802604B/zh active Active
- 2010-06-17 DK DK14150805.1T patent/DK2722035T3/en active
- 2010-06-17 DK DK16159225.8T patent/DK3045164T3/da active
- 2010-06-17 KR KR1020127001303A patent/KR101738502B1/ko active IP Right Grant
- 2010-06-17 HU HUE16159225A patent/HUE049477T2/hu unknown
- 2010-06-17 ES ES16159225T patent/ES2803648T3/es active Active
- 2010-06-17 JP JP2012516295A patent/JP6017956B2/ja active Active
- 2010-06-17 SI SI201030575T patent/SI2442790T1/sl unknown
- 2010-06-17 WO PCT/US2010/038979 patent/WO2010148190A1/en active Application Filing
- 2010-06-17 PT PT161592258T patent/PT3045164T/pt unknown
- 2010-06-17 PT PT107273179T patent/PT2442790E/pt unknown
- 2010-06-17 EP EP16159225.8A patent/EP3045164B1/en active Active
- 2010-06-17 DK DK10727317.9T patent/DK2442790T3/da active
- 2010-06-17 ES ES10727317.9T patent/ES2461617T3/es active Active
- 2010-06-17 LT LTEP16159225.8T patent/LT3045164T/lt unknown
-
2011
- 2011-11-15 ZA ZA2011/08384A patent/ZA201108384B/en unknown
-
2012
- 2012-04-26 HK HK12104110.3A patent/HK1163521A1/xx unknown
- 2012-04-26 HK HK14107529.9A patent/HK1194007A1/zh unknown
-
2014
- 2014-07-25 JP JP2014151427A patent/JP2014198729A/ja active Pending
-
2015
- 2015-04-20 US US14/690,617 patent/US9421265B2/en active Active
-
2016
- 2016-07-21 US US15/215,683 patent/US20160324967A1/en not_active Abandoned
- 2016-07-26 CY CY20161100735T patent/CY1117835T1/el unknown
- 2016-07-27 SM SM201600249T patent/SMT201600249B/it unknown
- 2016-07-27 JP JP2016146972A patent/JP2016183198A/ja active Pending
- 2016-07-27 HR HRP20160953TT patent/HRP20160953T1/hr unknown
-
2020
- 2020-06-19 HR HRP20200979TT patent/HRP20200979T1/hr unknown
- 2020-07-10 CY CY20201100637T patent/CY1123120T1/el unknown
-
2021
- 2021-05-05 AR ARP210101228A patent/AR122017A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2584858T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol | |
ES2924243T3 (es) | Composiciones oftálmicas que comprenden un antagonista muscarínico y agua deuterada | |
ES2627437T3 (es) | Composiciones de fosfolípido para cuidado de lentes de contacto y preservación de composiciones farmacéuticas | |
ES2301964T3 (es) | Preparado liquido acuoso que contiene acido 2-amino-3-(4-bromobenzoil)fenilacetico. | |
ES2644550T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol | |
ES2198127T3 (es) | Composiciones farmaceuticas autoclaveables que contienen un agente quelante. | |
ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
PT1819362E (pt) | Formulações tópicas de nepafenac | |
ES2404086T3 (es) | Formulaciones tópicas en solución que contienen un corticosteroide y una ciclodextrina | |
ES2337501T3 (es) | Preparacion oftalmica que comprende goma de xantano y terpenoide. | |
AR069438A1 (es) | Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica | |
JP2013525493A5 (es) | ||
JPWO2018066651A1 (ja) | 眼科用製品及び粘度低下抑制方法 | |
AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
JP2014214085A (ja) | オロパタジン含有水性組成物 | |
ES2294361T3 (es) | Colirios estables que contienen latanoprost como principio activo. | |
JP2013181020A (ja) | 眼科用組成物 | |
ES2460967T3 (es) | Método para la prevención de la degradación de una sustancia térmicamente inestable | |
ES2664053T3 (es) | Composición líquida acuosa que contiene ácido 2-amino-3-(4-bromobenzoil)fenil-láctico | |
JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
JP6161500B2 (ja) | ブロムフェナク含有組成物 | |
JP2015067607A (ja) | 複数の成分を配合した点眼剤 | |
AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
JP2019065003A (ja) | 安定化したシアノコバラミンを含有する水性組成物およびシアノコバラミンの安定化方法 | |
AR106691A1 (es) | Formulaciones oftálmicas de escualamina |